Phase II Trial of Lenalidomide/Rituximab +/- Dexamethasone in Relapsed/Refractory B-Cell Lymphomas or MCL Resistant to Rituximab


Phase II Trial of Lenalidomide/Rituximab +/- Dexamethasone in Relapsed/Refractory B-Cell Lymphomas or MCL Resistant to Rituximab
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Owen A O’Connor, MD, PhD (2/3/12)

Ahmadi T et al. Phase II trial of lenalidomide - rituximab +/- dexamethasone in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. Proc ASH 2011;Abstract 266.

Dr O'Connor is Professor of Medicine and Developmental Therapeutics and Director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York, New York.